Inhaled human insulin (Exubera®)

clinical profile and patient considerations

Anthony H. Barnett, Sri Bellary

Research output: Contribution to journalArticle

Abstract

Inhaled human insulin (Exubera®) is a rapid-acting regular human insulin administered by oral inhalation before meals. It provides a non-invasive alternative to multiple subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and type 2 diabetes. Compared with subcutaneous rapid-acting insulin analogs, Exubera provides equivalent HbA1c control. As a monotherapy or in combination with oral agents, Exubera also provides greater glycemic control than oral agents alone, at least in patients with high levels of HbA1c. Exubera demonstrates improved patient satisfaction compared with subcutaneous insulin or oral agents alone. When offered as a treatment option together with standard treatments in uncontrolled patients naive to insulin, Exubera increases acceptance of insulin therapy three-fold compared with patients offered standard regimens only. Exubera is well tolerated in comparison to subcutaneous insulin, with a similar incidence of mild to moderate hypoglycemia. Although cough is a common adverse effect early in therapy, this leads to treatment discontinuations in less than 1% of patients. Despite an increased incidence of insulin antibodies compared with subcutaneous administration, and a consistent but minor impact on pulmonary function, long-term safety data of up to 4 years continue to support the safety profile of Exubera.
Original languageEnglish
Pages (from-to)83-91
Number of pages9
JournalVascular Health and Risk Management
Volume3
Issue number1
Publication statusPublished - 2007

Fingerprint

Insulin
Insulin, Regular, Human
Short-Acting Insulin
Insulin Antibodies
Therapeutics
Safety
Incidence
Subcutaneous Injections
Secondary Prevention
Exubera
Patient Satisfaction
Type 1 Diabetes Mellitus
Hypoglycemia
Cough
Hyperglycemia
Type 2 Diabetes Mellitus
Inhalation
Meals
Lung

Bibliographical note

© 2007 Dove Medical Press Limited. Creative Commons Attribution Non-Commercial License

Keywords

  • Exubera
  • inhaled human insulin
  • hyperglycemia
  • diabetes

Cite this

@article{b07015407b6c409b8d4ff862dbde192d,
title = "Inhaled human insulin (Exubera{\circledR}): clinical profile and patient considerations",
abstract = "Inhaled human insulin (Exubera{\circledR}) is a rapid-acting regular human insulin administered by oral inhalation before meals. It provides a non-invasive alternative to multiple subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and type 2 diabetes. Compared with subcutaneous rapid-acting insulin analogs, Exubera provides equivalent HbA1c control. As a monotherapy or in combination with oral agents, Exubera also provides greater glycemic control than oral agents alone, at least in patients with high levels of HbA1c. Exubera demonstrates improved patient satisfaction compared with subcutaneous insulin or oral agents alone. When offered as a treatment option together with standard treatments in uncontrolled patients naive to insulin, Exubera increases acceptance of insulin therapy three-fold compared with patients offered standard regimens only. Exubera is well tolerated in comparison to subcutaneous insulin, with a similar incidence of mild to moderate hypoglycemia. Although cough is a common adverse effect early in therapy, this leads to treatment discontinuations in less than 1{\%} of patients. Despite an increased incidence of insulin antibodies compared with subcutaneous administration, and a consistent but minor impact on pulmonary function, long-term safety data of up to 4 years continue to support the safety profile of Exubera.",
keywords = "Exubera, inhaled human insulin, hyperglycemia, diabetes",
author = "Barnett, {Anthony H.} and Sri Bellary",
note = "{\circledC} 2007 Dove Medical Press Limited. Creative Commons Attribution Non-Commercial License",
year = "2007",
language = "English",
volume = "3",
pages = "83--91",
journal = "Vascular Health and Risk Management",
issn = "1176-6344",
publisher = "Dove Medical Press Ltd.",
number = "1",

}

Inhaled human insulin (Exubera®) : clinical profile and patient considerations. / Barnett, Anthony H.; Bellary, Sri.

In: Vascular Health and Risk Management, Vol. 3, No. 1, 2007, p. 83-91.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Inhaled human insulin (Exubera®)

T2 - clinical profile and patient considerations

AU - Barnett, Anthony H.

AU - Bellary, Sri

N1 - © 2007 Dove Medical Press Limited. Creative Commons Attribution Non-Commercial License

PY - 2007

Y1 - 2007

N2 - Inhaled human insulin (Exubera®) is a rapid-acting regular human insulin administered by oral inhalation before meals. It provides a non-invasive alternative to multiple subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and type 2 diabetes. Compared with subcutaneous rapid-acting insulin analogs, Exubera provides equivalent HbA1c control. As a monotherapy or in combination with oral agents, Exubera also provides greater glycemic control than oral agents alone, at least in patients with high levels of HbA1c. Exubera demonstrates improved patient satisfaction compared with subcutaneous insulin or oral agents alone. When offered as a treatment option together with standard treatments in uncontrolled patients naive to insulin, Exubera increases acceptance of insulin therapy three-fold compared with patients offered standard regimens only. Exubera is well tolerated in comparison to subcutaneous insulin, with a similar incidence of mild to moderate hypoglycemia. Although cough is a common adverse effect early in therapy, this leads to treatment discontinuations in less than 1% of patients. Despite an increased incidence of insulin antibodies compared with subcutaneous administration, and a consistent but minor impact on pulmonary function, long-term safety data of up to 4 years continue to support the safety profile of Exubera.

AB - Inhaled human insulin (Exubera®) is a rapid-acting regular human insulin administered by oral inhalation before meals. It provides a non-invasive alternative to multiple subcutaneous injections for the treatment of hyperglycemia in adult patients with type 1 and type 2 diabetes. Compared with subcutaneous rapid-acting insulin analogs, Exubera provides equivalent HbA1c control. As a monotherapy or in combination with oral agents, Exubera also provides greater glycemic control than oral agents alone, at least in patients with high levels of HbA1c. Exubera demonstrates improved patient satisfaction compared with subcutaneous insulin or oral agents alone. When offered as a treatment option together with standard treatments in uncontrolled patients naive to insulin, Exubera increases acceptance of insulin therapy three-fold compared with patients offered standard regimens only. Exubera is well tolerated in comparison to subcutaneous insulin, with a similar incidence of mild to moderate hypoglycemia. Although cough is a common adverse effect early in therapy, this leads to treatment discontinuations in less than 1% of patients. Despite an increased incidence of insulin antibodies compared with subcutaneous administration, and a consistent but minor impact on pulmonary function, long-term safety data of up to 4 years continue to support the safety profile of Exubera.

KW - Exubera

KW - inhaled human insulin

KW - hyperglycemia

KW - diabetes

M3 - Article

VL - 3

SP - 83

EP - 91

JO - Vascular Health and Risk Management

JF - Vascular Health and Risk Management

SN - 1176-6344

IS - 1

ER -